Telmisartan–Chlorthalidone Fixed-Dose Combination at Two Chlorthalidone Dose Levels versus Telmisartan in Uncontrolled Hypertension: A Phase III Trial

Clicks: 10
ID: 331944
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #80 of 85 articles by views in American Journal of Hypertension

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Evidence comparing different diuretic doses within fixed-dose combinations (FDCs) remains limited. We evaluated telmisartan/chlorthalidone FDCs according to chlorthalidone dose in patients with blood pressure (BP) inadequately controlled on telmisartan monotherapy. METHODS: In this randomized, double-blind trial, 254 patients with uncontrolled BP [sitting systolic blood pressure (SBP) ≥140 and <180 mmHg; sitting diastolic blood pressure (DBP) <110 mmHg] after a telmisartan run-in period were randomized (1:1:1) to receive either telmisartan/chlorthalidone FDCs (40/12.5 or 40/6.25 mg), or telmisartan 40 mg for 8 weeks. The primary endpoint was the change in sitting SBP from baseline to Week 8. RESULTS: At Week 8, telmisartan/chlorthalidone FDCs demonstrated greater reductions in sitting SBP compared with telmisartan monotherapy: least-squares mean differences were -9.5 mmHg [95% CI, -13.5 to - 5.6] for the 40/12.5 mg and -6.1 mmHg [95% CI, -10.4 to - 1.9] for the 40/6.25 mg. BP control rates (target BP: SBP/DBP <140/90 mmHg, or < 130/80 mmHg in patients with albuminuric chronic kidney disease or established cardiovascular disease) at Week 8 also favored telmisartan/chlorthalidone FDCs over telmisartan monotherapy (53.2% for the 40/12.5 mg and 43.0% for the 40/6.25 mg versus 32.9% for telmisartan 40 mg). Safety profiles were comparable among treatment groups. CONCLUSIONS: In patients inadequately controlled on telmisartan alone, FDCs of telmisartan with two different doses of chlorthalidone provided greater BP reduction than telmisartan monotherapy without increased safety risk, supporting its role as an effective and well-tolerated treatment option.
Reference Key
openalex_W7221070558 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Seung-Whan Lee, Jin‐Man Cho, Soon Jun Hong, Seung Hwan Han, Gyu Chul Oh, Seong Hwan Kim, Jung-Hoon Sung, Sang-Rok Lee, Gyung-Min Park, Hyun-Jae Kang, Jun-Hee Lee, Ji-Yong Choi, Kyung Hee Lim, CHEOL UNG CHOI, Kim Byeong-Keuk, Sang-Hyun Kim, In-Ho Chae
Journal American Journal of Hypertension
Year 2026
DOI
10.1093/ajh/hpag081
URL
https://doi.org/10.1093/ajh/hpag081
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.